Abrocitinib Clinical Trials
10 recruitingDrug
Phase 32Early Phase 11Phase 21
Showing 1–10 of 10 trials
Recruiting
Phase 3
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
Atopic Dermatitis
Pfizer500 enrolled31 locationsNCT06807281
Recruiting
Phase 3
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
Eczema
Pfizer150 enrolled40 locationsNCT06807268
Recruiting
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
Atopic DermatitisAtopic Dermatitis, Unspecified
Pfizer150 enrolled1 locationNCT06899204
Recruiting
Phase 2
Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome
Alopecia AreataAtopic Dermatitis
Icahn School of Medicine at Mount Sinai56 enrolled1 locationNCT07242638
Recruiting
A Study to Learn About the Study Medicine (Called Cibinqo) in People With Atopic Dermatitis
Pfizer1,100 enrolled1 locationNCT05391061
Recruiting
A Study of How Safe Abrocitinib (CIBINQO) is in Pregnant Women and Their Offspring
Atopic Dermatitis
Pfizer400 enrolled1 locationNCT05721937
Recruiting
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
Atopic DermatitisEczema
Pfizer183 enrolled30 locationsNCT05689151
Recruiting
Molecular Signatures in Inflammatory Skin Disease
Atopic DermatitisPsoriasis
Prof. Dr. Stephan Weidinger300 enrolled1 locationNCT03358693
Recruiting
Efficacy and Safety of JAK Inhibitors in Patients With AA: RWE Study
Alopecia AreataJanus Kinase Inhibitors
Second Affiliated Hospital, School of Medicine, Zhejiang University150 enrolled1 locationNCT06573593
Recruiting
Early Phase 1
Evaluation of the Efficacy and Safety of Methylprednisolone Combined With the JAK Inhibitors in the Treatment of Toxic Epidermal Necrolysis
Toxic Epidermal Necrolysis
Peng Zhang30 enrolled1 locationNCT06119490